Promethazine

Last updated

Promethazine
Promethazine.svg
Promethazine-based-on-xtal-3D-bs-17.png
Clinical data
Trade names Phenergan, others [1]
AHFS/Drugs.com Monograph
MedlinePlus a682284
License data
Pregnancy
category
  • AU:C
Routes of
administration 		By mouth, rectal, intravenous, intramuscular, topical
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 88% absorbed but after first-pass metabolism reduced to 25% absolute bioavailability [2]
Protein binding 93%
Metabolism Liver glucuronidation and sulfoxidation
Elimination half-life 10–19 hours [2] [3]
Excretion Kidney and Bile duct
Identifiers
  • (RS)-N,N-Dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.000.445 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C17H20N2S
Molar mass 284.42 g·mol−1
3D model (JSmol)
Chirality Racemic mixture
  • S2c1ccccc1N(c3c2cccc3)CC(N(C)C)C
  • InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3 Yes check.svgY
  • Key:PWWVAXIEGOYWEE-UHFFFAOYSA-N Yes check.svgY
   (verify)

Promethazine, sold under the brand name Phenergan among others, is a first-generation antihistamine, sedative, and antiemetic used to treat allergies, insomnia, and nausea. It may also help with some symptoms associated with the common cold [4] and may also be used for sedating people who are agitated or anxious, an effect that has led to some recreational use (especially with codeine). [5] [6] [7] Promethazine is taken by mouth (oral), as a rectal suppository, or by injection into a muscle (IM). [4]

Contents

Common side effects of promethazine include confusion and sleepiness; [4] consumption of alcohol or other sedatives can make these symptoms worse. [4] It is unclear if use of promethazine during pregnancy or breastfeeding is safe for the fetus. [4] [6] Use of promethazine is not recommended in those less than two years old, due to potentially negative effects on breathing. [4] Use of promethazine by injection into a vein is not recommended, due to potential skin damage. [4] Promethazine is in the phenothiazine family of medications. [4] It is also a strong anticholinergic, which produces its sedative effects. This also means high or toxic doses can act as a deliriant. [8]

Promethazine was made in the 1940s by a team of scientists from Rhône-Poulenc laboratories. [9] It was approved for medical use in the United States in 1951. [4] It is a generic medication and is available under many brand names globally. [1] In 2022, it was the 198th most commonly prescribed medication in the United States, with more than 2 million prescriptions. [10] [11] In 2022, the combination with dextromethorphan was the 260th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [10] [12]

Medical uses

Promethazine has a variety of medical uses, including:

Side effects

Some documented side effects include:

Less frequent:

Rare side effects include:

Because of the potential for more severe side effects, this drug is on the list to avoid in the elderly. [22] In many countries (including the US and UK), promethazine is contraindicated in children less than two years of age, and strongly cautioned against in children between two and six, due to problems with respiratory depression and sleep apnea. [23]

Promethazine is listed as one of the drugs with the highest anticholinergic activity in a study of anticholinergic burden, including long-term cognitive impairment. [24]

Overdose

Promethazine in overdose can produce signs and symptoms including CNS depression, hypotension, respiratory depression, unconsciousness, and sudden death. [25] Other reactions may include hyperreflexia, hypertonia, ataxia, athetosis, and extensor-plantar reflexes. [25] Atypically and/or rarely, stimulation, convulsions, hyperexcitability, and nightmares may occur. [25] Anticholinergic effects like dry mouth, dilated pupils, flushing, gastrointestinal symptoms, and delirium may occur as well. [25] Treatment of overdose is supportive and based on symptoms. [25]

Pharmacology

Promethazine, a phenothiazine derivative, is structurally different from the neuroleptic phenothiazines, with similar but different effects. [2] Despite structural differences, promethazine exhibits a strikingly similar binding profile to promazine, [26] another phenothiazine compound. Both promethazine and promazine exhibit comparable neuroleptic potency, with a neuroleptic potency of 0.5. [27] However, dosages used therapeutically, such as for sedation or sleep disorders, have no antipsychotic effect. [28] It acts primarily as a strong antagonist of the H1 receptor (antihistamine, Ki = 1.4 nM [29] ) and a moderate mACh receptor antagonist (anticholinergic), [2] and also has weak to moderate affinity for the 5-HT2A, [30] 5-HT2C, [30] D2, [31] [32] and α1-adrenergic receptors, [33] where it acts as an antagonist at all sites, as well. New studies have shown that promethazine acts as a strong non-competitive selective NMDA receptor antagonist, with an EC50 of 20 μM; [34] which might promote sedation in addition with the strong antihistaminergic effects of the H1 receptor, but also as a weaker analgesic. It does not, however, affect the AMPA receptors. [34]

Another notable use of promethazine is as a local anesthetic, by blockage of sodium channels. [33]

Binding to receptors in nM (Ki)
receptor Ki (nM)ref
α1A-adrenoceptor (Rat)32 [35]
α1B-adrenoceptor (Rat)21 [35]
α1D-adrenoceptor (Human)90 [35]
α2A-adrenoceptor (Human)256 [35]
α2B-adrenoceptor (Human)24 [35]
α2C-adrenoceptor (Human)353 [35]
Calmodulin (Human)60000 [36] [35] [37]
Calmodulin (Bovine)50000 [36] [37] [35]
Chloroquine resistance transporter (Plasmodium falciparum)85000 [38] [35]
D1 receptor (Human)1372 [35]
D2 receptor (Human)260 [35]
D3 receptor (Human)190 [35]
H1 receptor (Human)0.33 [35] -1.4 [39] [39] [35]
H2 receptor (Human)1146 [35]
M1 receptor (Human)3.32 [35]
M2 receptor (Human)12 [35]
M3 receptor (Human)4.15 [35]
M4 receptor (Human)1.06 [35]
M5 receptor (Human)3.31 [35]
NET (Human)4203 [35]
Prion protein (Human)8000 [40] [35]
5-HT1A receptor (Rat)1484 [35]
5-HT2A receptor (Human)19 [35]
5-HT2B receptor (Human)43 [35]
5-HT2C receptor (Human)6.48 [35]
5-HT6 receptor (Human)1128 [35]
SERT (Serotonin transporter) (Human)2130 [35]
Sigma1 receptor (Human)120 [35]
OCT1 (Human)35100 [41] [35]

Chemistry

Solid promethazine hydrochloride is a white to faint-yellow, practically odorless, crystalline powder. Slow oxidation may occur upon prolonged exposure to air, usually causing blue discoloration. Its hydrochloride salt is freely soluble in water and somewhat soluble in alcohol. Promethazine is a chiral compound, occurring as a mixture of enantiomers. [42]

History

Promethazine was first synthesized by a group at Rhone-Poulenc (which later became part of Sanofi) led by Paul Charpentier in the 1940s. [43] The team was seeking to improve on diphenhydramine; the same line of medical chemistry led to the creation of chlorpromazine. [44]

Society and culture

As of July 2017, it is marketed under many brand names worldwide: Allersoothe, Antiallersin, Anvomin, Atosil, Avomine, Closin N, Codopalm, Diphergan, Farganesse, Fenazil, Fenergan, Fenezal, Frinova, Hiberna, Histabil, Histaloc, Histantil, Histazin, Histazine, Histerzin, Lenazine, Lergigan, Nufapreg, Otosil, Pamergan, Pharmaniaga, Phenadoz, Phenerex, Phenergan, Phénergan, Pipolphen, Polfergan, Proazamine, Progene, Prohist, Promet, Prometal, Prometazin, Prometazina, Promethazin, Prométhazine, Promethazinum, Promethegan, Promezin, Proneurin, Prothazin, Prothiazine, Prozin, Pyrethia, Quitazine, Reactifargan, Receptozine, Romergan, Sominex, Sylomet, Xepagan, Zinmet, and Zoralix. [1]

Atosil syrup Atosil.jpg
Atosil syrup

It is also marketed in many combination drug formulations:

Recreational use

The recreational drug lean, also known as purple drank among other names, often contains a combination of promethazine with codeine-containing cold medication. [5]

Product liability lawsuit

In 2009, the US Supreme Court ruled on a product liability case involving promethazine. Diana Levine, a woman with a migraine, was administered Wyeth's Phenergan via IV push. The drug was injected improperly, resulting in gangrene and subsequent amputation of her right forearm below the elbow. A state jury awarded her $6 million in punitive damages.

The case was appealed to the Supreme Court on grounds of federal preemption and substantive due process. [45] The Supreme Court upheld the lower courts' rulings, stating that "Wyeth could have unilaterally added a stronger warning about IV-push administration" without acting in opposition to federal law. [46] In effect, this means drug manufacturers can be held liable for injuries if warnings of potential adverse effects, approved by the US Food and Drug Administration (FDA), are deemed insufficient by state courts.

In September 2009, the FDA required a boxed warning be put on promethazine for injection, stating the contraindication for subcutaneous administration. The preferred administrative route is intramuscular, which reduces the risk of surrounding muscle and tissue damage. [47]

Related Research Articles

<span class="mw-page-title-main">Neuroleptic malignant syndrome</span> Medical condition

Neuroleptic malignant syndrome (NMS) is a rare but life-threatening reaction that can occur in response to antipsychotics (neuroleptic) or other drugs that block the effects of dopamine. Symptoms include high fever, confusion, rigid muscles, variable blood pressure, sweating, and fast heart rate. Complications may include muscle breakdown (rhabdomyolysis), high blood potassium, kidney failure, or seizures.

<span class="mw-page-title-main">Trifluoperazine</span> Typical antipsychotic medication

Trifluoperazine, marketed under the brand name Stelazine among others, is a typical antipsychotic primarily used to treat schizophrenia. It may also be used short term in those with generalized anxiety disorder but is less preferred to benzodiazepines. It is of the phenothiazine chemical class. It was approved for medical use in the United States in 1959.

<span class="mw-page-title-main">Chlorpromazine</span> Antipsychotic medication

Chlorpromazine (CPZ), marketed under the brand names Thorazine and Largactil among others, is an antipsychotic medication. It is primarily used to treat psychotic disorders such as schizophrenia. Other uses include the treatment of bipolar disorder, severe behavioral problems in children including those with attention deficit hyperactivity disorder, nausea and vomiting, anxiety before surgery, and hiccups that do not improve following other measures. It can be given orally, by intramuscular injection, or intravenously.

<span class="mw-page-title-main">Diphenhydramine</span> Antihistamine medication

Diphenhydramine (DPH) is an antihistamine and sedative first developed by George Rieveschl and put into commercial use in 1946. It is available as a generic medication, and also sold under the brand name Benadryl among others. In 2021, it was the 242nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.

Anticholinergics are substances that block the action of the acetylcholine (ACh) neurotransmitter at synapses in the central and peripheral nervous system.

Postoperative nausea and vomiting (PONV) is the phenomenon of nausea, vomiting, or retching experienced by a patient in the post-anesthesia care unit (PACU) or within 24 hours following a surgical procedure. PONV affects about 10% of the population undergoing general anaesthesia each year. PONV can be unpleasant and lead to a delay in mobilization and food, fluid, and medication intake following surgery.

<span class="mw-page-title-main">Hydroxyzine</span> Antihistamine drug

Hydroxyzine, sold under the brand names Atarax and Vistaril among others, is an antihistamine medication. It is used in the treatment of itchiness, anxiety, insomnia, and nausea. It is used either by mouth or injection into a muscle.

<span class="mw-page-title-main">Cyclobenzaprine</span> Muscle relaxant medication

Cyclobenzaprine, sold under several brand names including, historically, Flexeril, is a muscle relaxer used for muscle spasms from musculoskeletal conditions of sudden onset. It is not useful in cerebral palsy. It is taken by mouth.

<span class="mw-page-title-main">Doxylamine</span> First-generation antihistamine used as a short-term sedative and hypnotic (sleep aid)

Doxylamine is an antihistamine medication used to treat insomnia and allergies, and—in combination with pyridoxine (vitamin B6)—to treat morning sickness in pregnant women. It is available over-the-counter and is typically sold under such brand names as Equate or Unisom, among others; and it is used in nighttime cold medicines (e.g., NyQuil) and pain medications containing acetaminophen and/or codeine to help with sleep. The medication is delivered chemically by the salt doxylamine succinate and is taken by mouth. Doxylamine and other first-generation antihistamines are the most widely used sleep medications in the world. Typical side effects of doxylamine (at recommended doses) include dizziness, drowsiness, grogginess, and dry mouth, among others.

<span class="mw-page-title-main">Orphenadrine</span> Muscle relaxant drug

Orphenadrine is an anticholinergic drug of the ethanolamine antihistamine class; it is closely related to diphenhydramine. It is a muscle relaxant that is used to treat muscle pain and to help with motor control in Parkinson's disease, but has largely been superseded by newer drugs. It is considered a dirty drug due to its multiple mechanisms of action in different pathways. It was discovered and developed in the 1940s.

<span class="mw-page-title-main">Dextromethorphan</span> Cough suppressant, antidepressant, and dissociative drug

Dextromethorphan (DXM), sold under the trade name Robitussin among others, is a cough suppressant used in many cough and cold medicines. In 2022, the US Food and Drug Administration (FDA) approved the combination dextromethorphan/bupropion to serve as a rapid-acting antidepressant in patients with major depressive disorder.

<span class="mw-page-title-main">Chlorprothixene</span> Typical antipsychotic medication

Chlorprothixene, sold under the brand name Truxal among others, is a typical antipsychotic of the thioxanthene group.

<span class="mw-page-title-main">Propiomazine</span> Chemical compound

Propiomazine, sold under the brand name Propavan among others, is an antihistamine which is used to treat insomnia and to produce sedation and relieve anxiety before or during surgery or other procedures and in combination with analgesics as well as during labor. Propiomazine is a phenothiazine, but is not used therapeutically as a neuroleptic because it does not block dopamine receptors well.

<span class="mw-page-title-main">Molindone</span> Antipsychotic medication

Molindone, sold under the brand name Moban, is an antipsychotic medication which is used in the United States in the treatment of schizophrenia. It is taken by mouth.

<span class="mw-page-title-main">Pentoxyverine</span> Antitussive / cough suppressant

Pentoxyverine (rINN) or carbetapentane is an antitussive commonly used for cough associated with illnesses like common cold. It is sold over-the-counter as Solotuss, or in combination with other medications, especially decongestants. One such product is Certuss, a combination of guaifenesin and pentoxyverine. The drug has been available in the form of drops, suspensions and suppositories.

<span class="mw-page-title-main">Zuclopenthixol</span> Typical antipsychotic medication

Zuclopenthixol, also known as zuclopentixol, is a medication used to treat schizophrenia and other psychoses. It is classed, pharmacologically, as a typical antipsychotic. Chemically it is a thioxanthene. It is the cis-isomer of clopenthixol. Clopenthixol was introduced in 1961, while zuclopenthixol was introduced in 1978.

<span class="mw-page-title-main">Cloperastine</span> Chemical compound

Cloperastine (INN) or cloperastin, in the forms of cloperastine hydrochloride (JAN) and cloperastine fendizoate, is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, and in some European countries. It was first introduced in 1972 in Japan, and then in Italy in 1981.

<span class="mw-page-title-main">Antihistamine</span> Drug that blocks histamine or histamine agonists

Antihistamines are drugs which treat allergic rhinitis, common cold, influenza, and other allergies. Typically, people take antihistamines as an inexpensive, generic drug that can be bought without a prescription and provides relief from nasal congestion, sneezing, or hives caused by pollen, dust mites, or animal allergy with few side effects. Antihistamines are usually for short-term treatment. Chronic allergies increase the risk of health problems which antihistamines might not treat, including asthma, sinusitis, and lower respiratory tract infection. Consultation of a medical professional is recommended for those who intend to take antihistamines for longer-term use.

<span class="mw-page-title-main">Cyamemazine</span> Antipsychotic medication

Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class which was introduced by Theraplix in France in 1972 and later in Portugal as well.

<span class="mw-page-title-main">Meclizine</span> Chemical compound


Meclizine, sold under the brand name Bonine, among others, is an antihistamine used to treat motion sickness and dizziness (vertigo). It is taken by mouth. Effects generally begin in an hour and last for up to a day.

References

  1. 1 2 3 4 "Promethazine international brands". Drugs.com. Retrieved 17 July 2017.
  2. 1 2 3 4 Strenkoski-Nix LC, Ermer J, DeCleene S, Cevallos W, Mayer PR (August 2000). "Pharmacokinetics of promethazine hydrochloride after administration of rectal suppositories and oral syrup to healthy subjects". American Journal of Health-System Pharmacy. 57 (16): 1499–505. doi: 10.1093/ajhp/57.16.1499 . PMID   10965395.
  3. ↑ Paton DM, Webster DR (1985). "Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines)". Clinical Pharmacokinetics. 10 (6): 477–97. doi:10.2165/00003088-198510060-00002. PMID   2866055. S2CID   33541001.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 "Promethazine Hydrochloride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 24 October 2018.
  5. 1 2 Agnich LE, Stogner JM, Miller BL, Marcum CD (September 2013). "Purple drank prevalence and characteristics of misusers of codeine cough syrup mixtures" (PDF). Addictive Behaviors. 38 (9): 2445–9. doi:10.1016/j.addbeh.2013.03.020. PMID   23688907.
  6. 1 2 British national formulary: BNF 74 (74 ed.). British Medical Association. 2017. p. 276. ISBN   978-0-85711-298-9.
  7. ↑ Malamed SF (2009). Sedation: A Guide to Patient Management. Elsevier Health Sciences. p. 113. ISBN   978-0-323-07596-1.
  8. ↑ Page CB, Duffull SB, Whyte IM, Isbister GK (February 2009). "Promethazine overdose: clinical effects, predicting delirium and the effect of charcoal". QJM. 102 (2): 123–131. doi: 10.1093/qjmed/hcn153 . PMID   19042969. S2CID   17677540.
  9. ↑ Li JJ (2006). Laughing Gas, Viagra, and Lipitor: The Human Stories behind the Drugs We Use. United Kingdom: Oxford University Press. p. 146. ISBN   978-0-19-988528-2 . Retrieved 9 July 2016.
  10. 1 2 "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  11. ↑ "Promethazine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  12. ↑ "Dextromethorphan; Promethazine Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  13. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Southard BT, Al Khalili Y (2019). "Promethazine". StatPearls. PMID   31335081. Creative Commons by small.svg  This article incorporates text available under the CC BY 4.0 license.
  14. ↑ "Promethazin - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste". Gelbe Liste Online (in German). Retrieved 22 May 2023.
  15. ↑ British National Formulary (March 2001). "4.6 Drugs used in nausea and Vertigo - Vomiting of pregnancy". BNF (45 ed.)..
  16. ↑ "Rhea Seddon Oral History". NASA Johnson Space Center Oral History Project. 10 May 2011. Retrieved 25 May 2021.
  17. ↑ "Promethazine (Phenergan)". Medicines A to Z. National Health Service. 27 October 2021. Archived from the original on 3 August 2023. Retrieved 2 October 2023.
  18. ↑ Schreiner NM, Windham S, Barker A (December 2017). "Atypical Neuroleptic Malignant Syndrome: Diagnosis and Proposal for an Expanded Treatment Algorithm: A Case Report". A&A Case Reports. 9 (12): 339–343. doi:10.1213/XAA.0000000000000610. PMID   28767476. S2CID   39699580.
  19. ↑ National Institute for Health and Care Excellence
  20. ↑ Hampton T (23 February 2005). "Promethazine Warning". JAMA. 293 (8): 921. doi:10.1001/jama.293.8.921-c.
  21. ↑ "Cordingley Neurology". Archived from the original on 21 December 2016. Retrieved 15 February 2008.
  22. ↑ NCQA's HEDIS Measure: Use of High Risk Medications in the Elderly Archived 1 February 2010 at the Wayback Machine
  23. ↑ Starke P, Weaver J, Chowdhury B (2005). "Boxed warning added to promethazine labeling for pediatric use". N. Engl. J. Med. 352 (5): 2653. doi: 10.1056/nejm200506233522522 . PMID   15972879.
  24. ↑ Salahudeen MS, Duffull SB, Nishtala PS (March 2015). "Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review". BMC Geriatrics. 15 (31): 31. doi: 10.1186/s12877-015-0029-9 . PMC   4377853 . PMID   25879993.
  25. 1 2 3 4 5 "Phenergan" (PDF). www.accessdata.fda.gov. Retrieved 30 September 2023.
  26. ↑ "promazine | Ligand Activity Charts | IUPHAR/BPS Guide to PHARMACOLOGY". www.guidetopharmacology.org. Retrieved 18 May 2023.
  27. ↑ Möller HJ, Müller WE, Bandelow B (2001). Neuroleptika – Pharmakologische Grundlagen, klinisches Wissen und therapeutisches Vorgehen (in German). Stuttgart: Wissenschaftliche Verlagsgesellschaft. ISBN   978-3-8047-1773-2.
  28. ↑ Benkert O, Hippius H (1995). Psychiatrische Pharmakotherapie. doi:10.1007/978-3-642-79084-3. ISBN   978-3-540-58149-9.
  29. ↑ Hill SJ, Young M (December 1978). "Antagonism of central histamine H1 receptors by antipsychotic drugs". European Journal of Pharmacology. 52 (3–4): 397–399. doi:10.1016/0014-2999(78)90297-2. PMID   32056.
  30. 1 2 Fiorella D, Rabin RA, Winter JC (October 1995). "The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis". Psychopharmacology. 121 (3): 347–56. doi:10.1007/bf02246074. PMID   8584617. S2CID   24420080.
  31. ↑ Seeman P, Watanabe M, Grigoriadis D, et al. (November 1985). "Dopamine D2 receptor binding sites for agonists. A tetrahedral model". Molecular Pharmacology. 28 (5): 391–9. PMID   2932631. Archived from the original on 29 August 2021. Retrieved 28 November 2011.
  32. ↑ Burt DR, Creese I, Snyder SH (April 1977). "Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain". Science. 196 (4287): 326–8. Bibcode:1977Sci...196..326B. doi:10.1126/science.847477. PMID   847477.
  33. 1 2 Prasad JP (2010). Conceptual Pharmacology. Universities Press. pp. 295, 303, 598. ISBN   978-81-7371-679-9 . Retrieved 27 November 2011.
  34. 1 2 Adolph O, Köster S, Georgieff M, Georgieff EM, Moulig W, Föhr KJ (August 2012). "Promethazine inhibits NMDA-induced currents - new pharmacological aspects of an old drug". Neuropharmacology. 63 (2): 280–291. doi:10.1016/j.neuropharm.2012.03.006. PMID   22507664. S2CID   35487146.
  35. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 "promethazine | Ligand Activity Charts | IUPHAR/BPS Guide to PHARMACOLOGY". www.guidetopharmacology.org. Retrieved 18 May 2023.
  36. 1 2 Bruno C, Cavalluzzi MM, Rusciano MR, Lovece A, Carrieri A, Pracella R, et al. (June 2016). "The chemosensitizing agent lubeluzole binds calmodulin and inhibits Ca(2+)/calmodulin-dependent kinase II". European Journal of Medicinal Chemistry. 116: 36–45. doi:10.1016/j.ejmech.2016.03.045. PMID   27043269.
  37. 1 2 Bolshan Y, Getlik M, Kuznetsova E, Wasney GA, Hajian T, Poda G, et al. (March 2013). "Synthesis, Optimization, and Evaluation of Novel Small Molecules as Antagonists of WDR5-MLL Interaction". ACS Medicinal Chemistry Letters. 4 (3): 353–357. doi:10.1021/ml300467n. PMC   4027439 . PMID   24900672.
  38. ↑ Deane KJ, Summers RL, Lehane AM, Martin RE, Barrow RA (May 2014). "Chlorpheniramine Analogues Reverse Chloroquine Resistance in Plasmodium falciparum by Inhibiting PfCRT". ACS Medicinal Chemistry Letters. 5 (5): 576–581. doi:10.1021/ml5000228. PMC   4027738 . PMID   24900883.
  39. 1 2 Nakai T, Kitamura N, Hashimoto T, Kajimoto Y, Nishino N, Mita T, et al. (August 1991). "Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia". Biological Psychiatry. 30 (4): 349–356. doi:10.1016/0006-3223(91)90290-3. PMID   1912125. S2CID   9715772.
  40. ↑ Vogtherr M, Grimme S, Elshorst B, Jacobs DM, Fiebig K, Griesinger C, et al. (August 2003). "Antimalarial drug quinacrine binds to C-terminal helix of cellular prion protein". Journal of Medicinal Chemistry. 46 (17): 3563–3564. doi:10.1021/jm034093h. PMID   12904059.
  41. ↑ Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, et al. (October 2008). "Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1". Journal of Medicinal Chemistry. 51 (19): 5932–5942. doi:10.1021/jm8003152. PMID   18788725.
  42. ↑ "RxList: Promethazine Description". 21 June 2007. Archived from the original on 11 September 2008. Retrieved 4 June 2008.
  43. ↑ Ban TA (2006). "The role of serendipity in drug discovery". Dialogues in Clinical Neuroscience. 8 (3): 335–44. doi:10.31887/DCNS.2006.8.3/tban. PMC   3181823 . PMID   17117615.
  44. ↑ "Paul Charpentier, Henri-Marie Laborit, Simone Courvoisier, Jean Delay, and Pierre Deniker". Science History Institute. 6 August 2015. Archived from the original on 20 March 2018. Retrieved 20 March 2018.
  45. ↑ Liptak A (18 September 2001). "Drug Label, Maimed Patient and Crucial Test for Justices". The New York Times. Retrieved 31 October 2008.
  46. ↑ Stout D (4 March 2009). "Drug Approval Is Not a Shield From Lawsuits, Justices Rule". The New York Times. Retrieved 4 March 2009.
  47. ↑ "Information for Healthcare Professionals: Intravenous Promethazine and Severe Tissue Injury, Including Gangrene". Food and Drug Administration . 15 August 2013.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.